Univariate and Multivariate Analysis of Risk Factors for Mortality... | Download Table
Ioannis VARTHALITIS | Head of Department | 1st Medical Oncology Dept
Ioannis VARTHALITIS | Head of Department | 1st Medical Oncology Dept
I. Varthalitis's research works | Hellenic Cooperative Oncology Group, Athens (HeCOG) and other places
a Number of delayed cycles (\2 cycles, C2 cycles), b number of delayed... | Download Scientific Diagram
Patient characteristics | Download Table
Ioannis VARTHALITIS | Head of Department | 1st Medical Oncology Dept
Ioannis VARTHALITIS | Head of Department | 1st Medical Oncology Dept
PDF) Case-Mix Adjustment Approach to Benchmarking Prevalence Rates of Nosocomial Infection in Hospitals in Cyprus and Greece
Effects of caspase inhibitors and thiol supplements on doxorubicin... | Download Scientific Diagram
Unadjusted (Observed) and Case Mix-Adjusted Prevalence Rates for... | Download Table
Reasons for secondary G-CSF use according to regimen (excluding... | Download Scientific Diagram
I Dimitriadis's research works
REMARK diagram for biomarker studies. | Download Scientific Diagram
Overall survival by RDI. Kaplan Meier overall survival curve for... | Download Scientific Diagram
Ioannis VARTHALITIS · Head of Department · 1st Medical Oncology Dept
Ioannis VARTHALITIS | Head of Department | 1st Medical Oncology Dept
Ioannis GIOULBASANIS | Head | MD, PhD | CHemotherapy
Patients' characteristics | Download Table
Ioannis VARTHALITIS | Head of Department | 1st Medical Oncology Dept
Œ½¼± •€¯¸µ„ ±½/¼¹ Athanasios Krystallis Aarchus Univ ... Athanasios Krystallis
Ioannis BOUKOVINAS | Bioclinic Thessaloniki, Thessaloníki | Oncology Unit
PDF) FEC versus sequential docetaxel followed by epirubicin/cyclophosphamide as adjuvant chemotherapy in women with axillary node-positive early breast cancer: a randomized study of the Hellenic Oncology Research Group (HORG) | I. Varthalitis
Unadjusted (Observed) and Case Mix-Adjusted Prevalence Rates for... | Download Table
PDF) A multicenter phase II study of pegylated liposomal doxorubicin in combination with irinotecan as second-line treatment of patients with refractory small-cell lung cancer
Ioannis VARTHALITIS | Head of Department | 1st Medical Oncology Dept
